Find out more about the people working on this project.
Dr Seshasailam Venkateswaran (Sesha) serves as the coordinator of ARREST-TB with the ultimate responsibility for the delivery of the project, having conceived the project and being the architect of the consortium. Sesha is a Chemical Engineer with a PhD in materials and polymer science with an industrial experience of ~16 years, in research and development, manufacturing, business development and managing international business. Sesha has worked with multi-nationals such as Unilever as well as SME’s – in India, UK, Spain and other European countries; and in the last 6 years within academia he has collaborated extensively in diverse work cultures in geographies spanning Brazil, India, UK, China and European countries (such as Spain, Italy, Denmark and Netherlands) and forged partnerships. He has worked in varied areas from discovering polymers to fulfil biomedical applications (such as bacteria resistant surfaces for medical devices) to industrial partnerships in molecular diagnostics. He is passionate about Antimicrobial resistance (AMR) and initiated a UK-India Newton project (~£1 M, joint grant value, relating to detection of co-selectors of AMR, focussing on Chennai, a city in South India), driving collaborations with the Indian Institute of Technology (Chennai and Roorkee). Sesha has firm ties with India and an extensive network in academia and industry in around the world, in particular, Europe and India.
Professor Mark Bradley heads the Scientific board of the ARREST-TB project and is also Director of the EPSRC Interdisciplinary Research Project Proteus that is focused on Optical Medical Imaging and he is an ERC Advanced Grant holder. Mark has a demonstrated capacity to work, publish and patent across the boundaries with a focus on the application of the tools of chemistry with the synthesis of materials and molecules to address and solve bio-medical questions and problems, resulting in over 350 publications and over 20 patents filed. Collaboration is the modus operandi of the Bradley group with over 30 active collaborations on-going. Mark has led a team of chemists and biologists specifically to create novel fluorescent “Smartprobes” with direct translation into human disease – with four first in human studies on-going.
Profesor Kev Dhaliwal is a Consultant Physician in Respiratory Medicine with a sub-specialist clinical also a Professor of Molecular Imaging & Healthcare Technology at the University of Edinburgh Medical School and as such has major clinical and scientific experience in Optical Imaging of Infection and has been driving forward the translation, clinical evaluation and trial designs leading to multiple clinical trials of optical imaging approaches in Respiratory Medicine. He leads a recently established Healthcare Technology Facility that incorporates medical device fabrication, chemical ingredient and formulation of chemical agents, ethics and regulatory knowledge in the Medical School. In this proposal he brings expert sub-specialist knowledge in Tuberculosis combined with 10 years experience of optical molecular imaging. He works alongside the Reference Mycobacterial laboratory in Edinburgh that provides category 4 microbiology facilities for testing chemical sensors on TB. He has developed global networks in TB sensing which will add additional value to the consortium.
Dr Elvira Williams (maiden name Bohl) completed her undergraduate degree in physical chemistry working on determining fluorescence quantum yields of riboflavin and riboflavin derivatives. After Elvira achieved a Diploma in Chemistry from the University of Kaiserslautern, Germany, in 2016 she successfully gained her PhD in Eleanor Campbell‘s group and graduated with a doctorate degree from the University of Edinburgh. In her research project, she worked extensively with femtosecond laser systems and ultra-high vacuum equipment. She investigated the highly excited electronic states of various fullerenes in the gas phase, in particular, superatom molecular orbitals (SAMOs). She also studied the excited states of different polycyclic aromatic hydrocarbons (PAHs) using theoretical (TD-DFT) and experimental (photoelectron spectroscopy) methods.
Following her PhD, Elvira gained industrial experience working on high power picosecond lasers at one of the world leading laser companies, Coherent. As a laser systems engineer, she was responsible for the production of solid-state laser systems with multiple amplification stages conforming to ISO 9001 and associated standards.
Pursuing her desire to develop novel optical systems and devices, she took a postdoctoral research associate position working for the Centre for Advanced Instrumentation (CfAI) at Durham University as part of the Proteus Project (www.proteus.ac.uk). In this project, she was responsible for the optical design of innovative medical instruments and the integration of multiple fluorescence imaging platforms including FLIM systems ready for clinical translation. She delivered this innovative imaging device ready for clinical trials in summer 2019.
Expanding her design knowledge towards low-cost systems, Elvira joined the Arrest TB project and the Mark Bradley group in April 2019. She is focused on developing simple frugal optical devices to detect tuberculosis at point-of-care in rural areas of India and Russia. These systems are aimed to work in conjunction with contrast agents for initial indication if the disease is present. She is excited to work on this project and be able to have a positive impact on unmet healthcare needs.
Having worked in leading academic institutions and major international companies in the UK and Europe she has extensive experience in project planning and optical instrumentation development. She is focused on exploring ideas for new applications to push forward scientific advances into focused product designs. Highly skilled in optical design and spectroscopy, specializing in novel optomechanical and miniaturized systems. Experience includes incorporating these technologies in areas ranging from fluorescence imaging techniques and laser spectroscopy to high power laser production, high harmonic generation and multiphoton systems.
Dan completed his Bachelor’s degree with Honours in Biological Chemistry and Drug Discovery at the University of Dundee. His Honours project was focused on palladium-catalysed multi-component reaction towards the synthesis of high-value scaffolds. Dan then worked at a start-up company in Glasgow, developing new peptide-based hydrogels for 3D cell culture, following which he started his doctoral studies at the University of Edinburgh in the group of Professor Mark Bradley. As part of the IMPACT project (an inter-disciplinary EPSRC research project), he developed prodrug activation systems that utilise electro- and photo-chemical actuators and delivered them through discovery stages to biological validation. This project expanded Dan’s skills and interest in chemistry, biology and engineering. Following his PhD, Dan started as a post-doctoral research associate as part of the ARREST-TB team, developing low-cost solutions for the simple and robust diagnosis of tuberculosis.
Mavys Tabraue Chavez is the – Senior Assay Development Scientist at DestiNA. Mavys joined DestiNA in March 2013, after several years of experience in biotech companies. She has been responsible for the integration and development of DestiNA SMART Nucleobases and probes for colorimetric assays, including the Master Diagnostica detection platforms and DestiNA spin-tubes. She completedher PhD in Medicinal Chemistry from the University of Granada, working on the design and synthesis of new HDAC inhibitors as anticancer drugs.
Juan J. Díaz-Mochón is a co-founder and CSO of DestiNA Genomics Ltd and the inventor of its core technology. He completed his PhD in Pharmacy from the University of Granada in 2001. He has enjoyed a distinguished academic career in Spain, Italy, and in the UK. As CSO of the company, he is responsible for on-time delivery of proof of concept studies, sign-off on experiments and scientific collaborations undertaken by the Company, and the quality and performance of the Company’s reagents and kits.
Salvatore Pernagallo is the operations director of DestiNA Genomics Ltd with the responsibility of identifying new product and application opportunities for the company and ensuring the DestiNA technology development and management of collaborative projects. He joined DestiNA in April 2011 initially as a senior scientist and subsequently as product development manager. He has a B.Sc. and M.Sc. in cellular and molecular biology and a M.D in genetics from the University of Catania (Italy). He earned his Ph.D. degree in chemistry and PostDoc in tissue engineering from the University of Edinburgh.
Juan Enrique Cruz Romera is the Administrator and Legal Representative of DestiNA Genomica S.L.Hereceived his BSc in Economy in 2010 and an Executive MBA in R&D Management at the University of Granada. He is a young entrepreneur who has set up of a number of startups, including the incorporation of the Spanish subsidiary DestiNA Genomica S.L. He is the legal representative of DestiNA Genomica S.L. and manager of the activities in Spain since he joined in February 2012.
Bárbara López Longarela is the Assay Development Scientist at DestiNA Genomics Ltd. She completed her Degree in Biotechnology from the University of Oviedo (Asturias, Spain) in 2013, developing her final project in detection of viral strains using bioinformatics and multiplex PCR techniques. In 2014, she finished the Master in Molecular Biology Applied to Biotechnological Companies (BioEnterprise) at the University of Granada (Granada, Spain) and joined DestiNA to perform her master’s thesis focused on the road-map of diagnostic products. Barbara became full DestiNA staff member in 2015.
Mario Antonio Fara is a Senior Chemist at DestiNA Genomics Ltd. Antonio graduated in chemistry at the Universita’ Degli Studi Di Sassari, on the beautiful island of Sardinia (Italy). He then joined the research group of Professor Mark Bradley at the University of Edinburgh, where he was awarded a PhD degree in Chemistry in 2010. After gaining working experience in different companies, Antonio joined DestiNA Genomics Ltd in September 2014 with the responsibility for the chemistry R&D. Antonio has many years of experience in the design and synthesis of peptides, PNA and small molecules and has played a central role in negotiating with chemical suppliers for contract synthesis and materials supply.
Hugh Ilyine is the CEO and a co-founder of DestiNA Genomics Ltd. An entrepreneur with more than 20 years international experience in biotechnology and multinational corporations, he has covered start-ups through to multi-country fund raising and stock listings on UK AIM and the Australian Stock Exchange. Hugh brings a wealth of experience in industrial product marketing and negotiation of multi-million dollar technology licenses.
Prof. Marc Desmulliez is Deputy Head of the Institute of Sensors, Signals and Systems at Heriot-Watt University. His research interests cover Advanced Manufacturing Techniques, Microwave Sensing, Electrochemical Sensors and Nature Inspired Engineering. He has co-authored over 470 publications and holds 8 patents. He span-out also 3 companies, one of them, MicroSense Technologies Ltd, in charge of reducing waste in the food & drink industries. Marc is leading the activity related to sensing, and assists Dr Helen Bridle in design, manufacturing and testing microfluidic network.
Dr Helen Bridle is an Associate Professor at Heriot-Watt University researching lab-on-a-chip systems, in which liquids are manipulated in microchannels the size of a single human hair. Her research group uses these systems to process drinking water samples to detect pathogens as well as in the purification of stem cell products for medical applications. Dr Bridle won the Royal Society of Edinburgh Innovator’s Prize for Public Engagement in 2016 and lead involved in numerous outreach activities, including science festivals, schools projects and festival shows as well as organising activities with the British Science Association Edinburgh branch. Helen is leading the dissemination section of the project.
Gerard Cummins is a postdoctoral researcher at Heriot-Watt University. Since being awarded his PhD in 2011 from the University of Edinburgh, he has amassed over 20 journal papers and a further 20 conference proceedings (with >420 citations according to Google Scholar), six invited talks in the UK and France, and won the National Instruments Engineering Impact Award 2018 for Most Innovative Research for his work on the Sonopill project. His research interests include microsystems, biomedical sensing and medical device development.
Dr. Sumanth Kumar Pavuluri, B.Tech, MSc, PhD is currently a Post-Doctoral Research Associate with Heriot-Watt University.
Dr. Pavuluri after completing his PhD in 2011 on micro machined antennas. In 2008, he has worked on highly sensitive micro machined microwave sensors for biological and chemical material detection based on waveguides loaded with a frequency selective surface. This work was a finalist in IEEE microwave theory and techniques (MTT) microwave measurement competition 2009. He also worked on Frequency Agile Microwave Oven Bonding System (FAMOBS) from February 2009 to October 2011 and developed patentable new generation open-ended oven prototypes for uniform and efficient curing of the microelectronic chips. This project has reached a technology readiness level of 5. He also worked on commercial automated Remote sensing device for road surfaces in 2012. After working on a Scottish Enterprise high growth spin out project on a patented sensor system product for reducing wastage in the food & drink industries from 2015 to middle of 2017, Dr Pavuluri has successfully spun out a company MicroSense technologies Limited along with Prof. Marc Desmulliez. MicroSense was joint 2016 winner of the Converge Challenge, the Scottish company creation competition and has been commended in 2018 IET (The institution of Engineering and Technology) innovation awards. MicroSense has also featured recently in January 2019 in BBC showcasing a new product development from the company.
In 2017 and 2018, Dr Pavuluri has been a member of Heriot‐Watt group in the EPSRC-funded Sonopill project, working on the electronics design and packaging of ingestible medical devices that are for various exploratory sensor systems for integration into capsules.
Dr. Pavuluri’s current research interests include medical diagnostics, medical electronics including telemetry and packaging, novel micro fabrication and micromachining methods for RF and acoustic devices for bio medical applications. Other areas of interest are microwave sensing, curing, and integrated circuit packaging.
Riccardo Manganelli obtained his PhD in Microbiology in 1995 at the University of Siena. During his PhD he worked on conjugative transposons of Gram positive bacteria and their biotechnological use. From 1995 to 2000 he moved to the United States, first in North Carolina, and then in New York, where he was a post doc in Issar Smith lab at the Public Health Research Institute. Here, he started to study Mycobacterium tuberculosis (Mtb) with his main interest the relationship between virulence and global transcriptional regulation. In 2000 RM moved to the University of Padova, Italy, where he is Professor of Microbiology. In Padova, he established his own group whose research lines include the study of sigma factors and global regulation of gene expression in Mtb, but also the development of tools for the genetic manipulation of mycobacteria as well as the development of new antitubercular drugs and diagnostics.
Luiza Barzon is the Associate Professor of Medical and biotechnology laboratory techniques at Padova University. MD at the Operative Unit of Microbiology and Virology, of the Azienda Ospedaliera of Padova from 2002 – to date. Head of the Molecular Diagnostics Unit and High Specialty in Molecular Diagnostics at the Operative Unit of Microbiology and Virology, of the Azienda Ospedaliera of Padova since, from 2007 – to date. Coordinator of the Section on Vector-borne infections of the Reference Regional Laboratory, Veneto Region, Italy, from 2005 – to date. Research fields include investigation of pathogen-host interactions, with focus on the role of host microRNA in disease pathogenesis; epidemiology, diagnosis and pathogenesis of vector-borne viral infections; development of disease models of human infections by using induced-pluripotent stem cell and genome editing technologies; application of novel molecular technologies to develop new diagnostic tools for infectious diseases. Author of about 200 articles in peer-reviewed journals indexed in PubMed; total citations = 5387; H-index = 37 (source Scopus).
Cristina Ress is the Head of Biomedical Business Unit at OPTOI. She has a M.Sc. in Biotechnology (Functional Genomics and Proteomics), a 2nd level professional Masters in NEMS/MEMS (Nano and Micro Electro-Mechanical Systems) and a PhD in ICT. In 2011, she joined the R&D Department of OPTOI Microelectronics and since 2012 has worked as Head of the Biomedical team, dealing with innovative optical and electrochemical sensors for biological and medical applications. She is the project coordinator of the H2020-MSCA-RISE-2015 project and she leads the OPTOI team in this project.
Roberta Ruffilli is currently a research engineer at Optoi. She had a master degree in biomedical engineering from the University of Genova (Italy) and a PhD in materials science from the University of Toulouse (France). Her research focused on the investigation of physical failure mechanisms of semiconductor-based devices for applications in the automotive industry, in collaboration with Freescale Semiconductors company and CEMES-CNRS laboratory (Toulouse). Her areas of expertise are electron and ion microscopy and sample preparation techniques of both soft (polymers and biological samples) and hard (metals) materials. She joined ARREST-TB project in April 2019, working on the development and test of the detection kits.
Mirko Erspan is a Senior Electronics Engineer at OPTOI. In the past, he worked on development of smart interface and microelectronic devices and systems, focusing on the RF MEMS switches packaging issues on the field of radiofrequency for high-end and aerospace applications. In this project, he works on the manufacturing of core electronics and sensors interfaces of the device.
Matteo Bregoli is the head of the Research & Development Unit at OPTOI and holds a degree in telecommunication engineering and has been employed as R&D design engineer in OPTOI since 2005. His current work is focused on the design and development of optoelectronic / microelectronic devices for space applications. Lately, his duties have been extended to the accountability for the running R&D activities. In this project he globally supervises the activity managing budget administration and administrative matters.
Dr. Antonio Martínez-Murcia (B.Sc. Biochemist/Molecular Biologist, Valencia University 1987; Ph.D. Microbiology, Reading University, UK, 1993), professor of microbiology (Molecular Pathogenicity and Vaccines) at the University “Miguel Hernandez”, Orihuela, Alicante, where also was promoter and director of the “Unidad de Diagnóstico Molecular” (2001). He counts with 30 years’ experience in genetic analysis applied to bacterial phylogeny, evolution, taxonomy, typing, identification and molecular microbial ecology. He has participated in over 40 national and international financed projects, including “C.L.E.A.N.” Coastal Lagoon Eutrophication and Anaerobic Processes, European Community Environment Research Program (1992-1995), AQUACHIP FP5 (2001-2003), CLINICALAIR EUREKA 3350/F1172 2005-2006, HEALTHY-WATER FP6 (2006-2009), and AQUAVALENS-FP7 (2013-2018). He is co-author of >80 papers in peer-reviewed journals and book chapters, a patented PCR method (1994), co-director of 8 doctoral theses, and has described 15 new bacterial species. Active member of the “Aeromonas Working-group” of the “International Sub-Committee on Vibrionaceae, Aeromonadaceae, and related genera” (International Committee on Systematics of Prokariotes). Promoter and director of GENETIC ANALYSIS STRATEGIES SL, developing qPCR assays for > 300 different pathogens of interest in veterinary, food, water, and clinical environment. Several biotech entrepreneur activities and innovations were awarded in 2002, 2012, and 2015.
Aaron Navarro García has a B.Sc. in Biotechnology (University of Alicante, 2001), B.Sc. in Biochemistry (University “Miguel Hernandez”, 2003), Ph.D. Molecular Biology (University “Miguel Hernandez”, 2011). Since 2013, responsible for the R&D department at GPS™. Participated in the European project AQUAVALENS-FP7 (2013-2018) where several innovative products were provided. He was part of the Organizing Committee of the X SEM Congress of Microbiology of the Aquatic Environment. Elche / Orihuela, 7-9 September, 2014. In recent years, he has been co-author of 8 scientific publications in high-impact international journals and has presented several communications at international congresses and symposia.
Adrián Garcia Sirera graduated in Biotechnology, Miguel Hernandez University, 2014. Master in Food Science and Engineering in collaboration with the Institute of Agrochemistry and Food Technology (IATA), Polytechnic University of Valencia, 2016. Master in Molecular Approaches in Health Sciences in collaboration with the Institute of Biomedicine of Valencia (IBV), University of Valencia, 2017. Technician in GENETIC ANALYSIS STRATEGIES, S.L since 2018
Gema Bru Amoraga Has a degree in Biology (speciality in health), University of Alicante, 2011. Master in Clinical Bio-pathology and Biotechnology (in collaboration with the Genetic Diagnosis Unit at Hospital of Elche), University of Alicante, 2012. During last 7 years in GENETIC ANALYSIS STRATEGIES was responsible of the Production and Quality. Participation in the European project AQUAVALENS. Member of the Organizing Committee of the X SEM Congress of Microbiology of the Aquatic Environment. Elche/Orihuela, 7-9 September 2014. Co-author of some communications and scientific papers.
Srikanth Tripathy is a physician working for the Indian Council of Medical Research (ICMR) since 1986 and has been involved earlier with research on TB in HIV infected individuals in the Pune region from 1988 till 2013. He has also been involved in research related to leprosy, tuberculosis, and HIV in the Agra region in north India while Director of the National JALMA Institute for Research in Leprosy and Other Mycobacterial Diseases (NJIL&OMD). Since Dec 2015, He has been working at the National Institute for Research in Tuberculosis (NIRT) in Chennai as the Head of the HIV Laboratory and since Oct 2016 as the Director in Charge at the National Institute for Research in Tuberculosis. Currently, he is involved with studies related to clinical trials for the management of tuberculosis and the development of new drug for tuberculosis. He has 102 publication in both national and international journals in the fields of HIV and tuberculosis.
In 1995, Professor Larisa N. Chernousova founded the first Russian laboratory of molecular genetic diagnosis of tuberculosis, based on the Department of Microbiology of the Central Tuberculosis Research Institute, and in 2008 she headed the Department of Microbiology. In 2015, under her leadership, the Department of Microbiology was certified by the World Health Organization as the Center of Excellence of the WHO Supranational Reference TB Laboratories Network. Prof. L.Chernousova is a Doctor of Biological Science, a specialist in the diagnosis of bacterial infections, clinical microbiology, and biotechnology. Prof. L.Chernousova is one of the leading specialists of the CTRI in Basic Research. Over the years, she has created a close-knit team of researchers and technical personnel. She directs all areas of the Department’s work devoted to both basic and applied research in phthisiology. She is the head of the Center of Excellence of the WHO Supranational Reference TB Laboratories Network, a member of the Thematic Working Group on Laboratory Diagnosis of Tuberculosis at the High Level Working Group on Tuberculosis of the Ministry of Health of the Russian Federation and WHO, a member of the expert group on laboratory diagnosis of tuberculosis under the Federal System of external quality assessment of clinical laboratory studies of the Russian Federation, a member of the I.I. Mechnikov All-Russian Scientific and Practical Society of Epidemiologists, Microbiologists and Parasitologists; a member of the Association of Russian TB Specialists and the National Association of TB Specialists. She is a Member of the Scientific Council of the Central Tuberculosis Research Institute and the Editorial Board of the journals Bacteriology and CTRI Bulletin. She gives lectures and holds seminars for graduate students and residents of CTRI and laboratory doctors from the Russian Federation and the CIS countries. Under the leadership of prof. L.Chernousova 11 candidate and 2 doctoral dissertations were defended. She has co-authored over 170 publications and holds 5 patents.
Tatyana began to work under the guidance of prof. Larisa Chernousova in the Laboratory of Molecular Diagnostics of the Central Tuberculosis Research Institute since its founding in 1995, when she was a student at the Pirogov Russian Medical University and perform her master’s thesis focused on the PCR-based diagnostics of tuberculosis. Tatyana obtained his PhD in Microbiology in 2005. During his PhD she worked on modeling latent tuberculosis in mice. Now her area of scientific interest is focused on the study of non-tuberculous mycobacteria (species diagnosis, determination of the genetic determinants of drug resistance). Tatyana coordinates all the experimental work in the department for testing new drugs and diagnostics in the framework of Russian and international projects. She is a Clinical Trial Laboratory Manager, TB Alliance. She has co-authored over 100 publications and holds 3 patents.
Sofya is a senior research associate at the Department of Microbiology of the Central Tuberculosis Research Institute. In 1998, she finished the Master in the Pirogov Russian State Medical University with a degree in biochemistry and joined at the Laboratory of Molecular Diagnostics of Tuberculosis of the Central Tuberculosis Research Institute (CTRI). In 2008, she completed her PhD in Microbiology, working on a study of the biological properties of Mycobacterium tuberculosis of different genotypic lines. Her research interests include resistance, fitness, virulence and transmission M. tuberculosis. Sofya is a Member of Russian and international scientific projects on the development of new anti-TB drugs and diagnostics. In this project, Sofya is a PI of a Russian working group, coordinating the concerted efforts of the laboratory and clinical units, monitoring the timely fulfillment of project obligations and being responsible for the preparation of reporting documentation. She has co-authored over 80 publications and holds 3 patents.
Elena has been working in the Department of Microbiology of the CTRI since 1995 under the guidance of prof. Larisa Chernousova on the development of molecular genetic diagnosis of tuberculosis in Russia. From 2014 to the present, she has been in charge of the laboratory of microbiological diagnosis of tuberculosis in the Department of Microbiology. In the laboratory, under her leadership, the latest methods of diagnosing tuberculosis and mycobacteriosis, determining the drug resistance of the pathogen are introduced. Elena is actively collaborates with the microbiological laboratories of regional TB dispensaries. She is a member of Russian and international scientific projects on the development of new anti-TB drugs and diagnostics. She has co-authored over 90 publications and holds 2 patents.
In 1991 Natalia graduated from the Medical Institute. Since 1991 – professional activities connected with the Central TB Research Institute, Moscow, Russia. From 2017 to the present time she is the acting Chief Researcher of the Clinical and Diagnostic Department of the CTRI. Natalia successfully combines her scientific activity and clinical work, as Head of the Clinical and Diagnostic Department of the CTRI (2017 – the present time). Her scientific research is devoted to the study of the pathogenetic therapy mechanisms in the complex treatment of patients with destructive pulmonary TB and is a scientific achievement of the national level. Currently Natalia actively participates in studies on the diagnosis of respiratory TB in patients with late stage of the HIV-infection and in patients with chronic kidney disease at the terminal stage before and after kidney transplantation. Natalia devotes most of her scientific activity to differential diagnosis of pulmonary TB and other respiratory diseases, in this area by her were developed and scientifically proven diagnostic algorithms that are widely introduced into clinical practice. She has co-authored over 100 publications and holds 2 patents.
Prof. Sai Siva Gorthi is the founder director of ShanMukha Innovations. Prof. Sai Siva Gorthi obtained his B.Tech from Jawaharlal Nehru Technological University (JNTU), Hyderabad in 2003, M.Sc (Engg) in Optical Metrology from Indian Institute of Science in 2006 and PhD in Optical Metrology from Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland in 2010. He was employed as a post-doctoral researcher in Optofluidics at the Rowland Institute at Harvard University, Boston, USA from 2010-2012. He joined the Department of Instrumentation and Applied Physics, IISc in 2012 as an Assistant Professor, where he is currently an Associate Professor.
Arun B heads product and customer development at ShanMukha Innovations. He has a Bachelor’s degree in Physics and Master’s degree in Computer Science and Engineering from the Indian Institute of Science, Bangalore. He has 18 years experience in technology and product development at GE Healthcare where he worked on number of global products including CT, X-Ray, MRI and Mammography.